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Background. Tumor necrosis factor (TNF) is associated with the development of inflammatory pathologies.
Antibodies and soluble TNF (solTNF) receptors that neutralize excessive TNF are effective therapies for inflammatory
and autoimmune diseases. However, clinical use of TNF inhibitors is associated with an increased risk of infections.
Methods. A novel dominant-negative (DN) strategy of selective TNF neutralization, consisting of blocking
solTNF while sparing transmembrane TNF (tmTNF), was tested in mouse models of mycobacterial infection and
acute liver inflammation. XENP1595, a DN-TNF biologic, was compared with etanercept, a TNF receptor 2
(TNFR2)–IgG1 Fc fusion protein that inhibits murine solTNF and tmTNF.
Results. XENP1595 protected mice from acute liver inflammation induced by endotoxin challenge in Mycobac-
terium bovis bacillus Calmette-Guérin (BCG)–infected mice, but, in contrast to etanercept, it did not compromise
host immunity to acute M. bovis BCG and Mycobacterium tuberculosis infections in terms of bacterial burden, gran-
uloma formation, and innate immune responses.
Conclusions. A selective inhibitor of solTNF efficiently protected mice from acute liver inflammation yet main-
tained immunity to mycobacterial infections. In contrast, nonselective inhibition of solTNF and tmTNF suppressed
immunity to M. bovis BCG and M. tuberculosis. Therefore, selective inhibition of solTNF by DN-TNF biologics may
represent a new therapeutic strategy for the treatment of inflammatory diseases without compromising host
immunity.
Tumor necrosis factor (TNF) is involved in many hu-
man inflammatory diseases, and its inhibition by TNF
receptor fusion proteins (such as etanercept) or anti-
TNF antibodies (such as infliximab and adalimumab)
has proved to be highly efficacious in the treatment of
rheumatoid arthritis, Crohn disease, and ulcerative co-
litis [1– 4]. However, the large number of patients
treated with TNF inhibitors has revealed an increased
risk for opportunistic infections, including either newly
acquired or reactivated tuberculosis [5–10]. Several
studies using mouse genetic models of TNF inhibition
have predicted an increased susceptibility to infections
and provide accumulating evidence implicating TNF as
a key factor in host defense against mycobacterial infec-
tions. Impaired granuloma formation, reduction in bac-
tericidal mechanisms, and alteration of mycobacterially
induced Th1 immune responses have all been observed
in mice defective in TNF signaling [11–18]. These find-
ings have recently been supported by results obtained
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using anti–murine TNF antibodies and soluble TNF (solTNF)
receptors in mouse models of acute tuberculosis [19]. Although
mouse models of acute tuberculosis may not fully reflect the
complexities of the clinical use of anti-TNF biologics, these re-
ports provide a potential explanation for the increased risk of
mycobacterial infections associated with anti-TNF treatment.
TNF is synthesized as a 26-kDa transmembrane TNF
(tmTNF) precursor that is cleaved by membrane-bound TACE
(TNF-– converting enzyme) to generate a 17-kDa solTNF mol-
ecule [20, 21]. Using genetic models (transgenic tmTNF in TNF/
lymphotoxin- (LT)/ and tmTNF knock-in mice), we have
shown elsewhere that tmTNF induces an efficient cell-mediated
immune response to Mycobacterium bovis bacillus Calmette-
Guérin (BCG) infection and confers protection against acute
Mycobacterium tuberculosis infection but does not fully protect
against long-term M. tuberculosis infection, as also reported by
others [22–25]. To date, in vivo studies of the roles played by
solTNF and tmTNF in infection have been limited to such ge-
netically modified mice. However, tmTNF is essential not only
in immune responses to infection but also in the development of
a normal lymphoid structure [26]. Given the abnormal develop-
ment of the immune system in TNF/ and tmTNF knock-in
mice, pharmacological studies of TNF inhibitors in normal mice
may better model the therapeutic use of anti-TNF biologics in
humans.
The growing literature establishing the importance of tmTNF
in immunity has generated support for a hypothesis that selec-
tively inhibiting solTNF while sparing tmTNF may reduce in-
flammation yet maintain the host response to pathogens. A
novel class of TNF inhibitors, dominant-negative (DN) TNF
biologics, antagonizes solTNF but not tmTNF and is active in
attenuating experimental arthritis [27]. These biologics rap-
idly exchange subunits with native solTNF to form inactive
mixed heterotrimers, eliminating native solTNF homotri-
mers without inhibiting tmTNF [27, 28]. The selectivity of
this class of biologics for solTNF contrasts with other anti-
TNFs, including etanercept, infliximab, and adalimumab,
which inhibit both tmTNF and solTNF [28 –33]. Recent stud-
ies have shown that DN-TNF biologics such as XENP1595 are
effective in reducing inflammation in mouse models of ar-
thritis and Parkinson disease but, in contrast to nonselective
inhibitors, do not suppress resistance to Listeria monocytoge-
nes infection [28, 34]. The present study analyzes the effects of
XENP1595 on host defense against M. bovis BCG and M. tu-
berculosis infections and on protection against endotoxin-
induced liver inflammation in M. bovis BCG–infected mice.
We used etanercept as a comparator biologic that inhibits
both solTNF and tmTNF [4, 28 –31] and, unlike the anti-TNF
antibodies infliximab and adalimumab, neutralizes TNF in
mice [28, 35–37]. The data show that XENP1595 efficiently
protected against endotoxin-mediated hepatotoxicity in
M. bovis BCG–infected mice while preserving immunity
against M. bovis BCG and M. tuberculosis infections, presum-
ably via maintenance of physiological tmTNF signaling.
METHODS
Animals. C57BL/6 mice (Charles River Laboratories) and
TNF/mice [24] were maintained under conventional conditions
in the animal facilities of the Medical Faculty, University of Geneva,
and the Transgenose Institute, Orleans, France. Experiments were
done in accordance with institutional guidelines and were approved
by the Centre Médical Universitaire and the French Regional Ethi-
cal Committee on Animal Experimentation.
Reagents. The Escherichia coli–produced DN protein
XENP1595 is a modified version of human solTNF (UniProtKB/
Swiss-Prot entry P01375) that contains mutations Y87H and
A145R to eliminate binding to and signaling through TNF re-
ceptors TNFR1 and TNFR2 [27, 28]. The protein contains mu-
tations C69V, C101A, and R31C to allow for site-specific pegy-
lation at C31 to extend in vivo half-life and reduce potential
immunogenicity. Etanercept, a human TNFR2–IgG1 Fc fusion
protein that sequesters both solTNF and tmTNF [4, 28 –31], was
obtained from a pharmacy (RxUSA). The vehicle solution was
PBS (pH 8) with 10% glycerol in M. bovis BCG infection and
saline in M. tuberculosis infection.
Reagent administration during M. bovis BCG and M. tuber-
culosis infections. Reagents (vehicle, etanercept, and XENP1595;
30 mg/kg/dose) were administered intraperitoneally 1 day before
infections and continued twice a week during the infection. The
doses and dosing regimen selected are in accord with results re-
ported elsewhere for XENP1595 and etanercept [28] and a murine
homologue of etanercept [19]. Mice were infected intravenously
with 1  107 living M. bovis BCG Pasteur strain 1173 P2 and
killed 2 or 4 weeks after infection. Pulmonary infection with M.
tuberculosisH37Rv (Pasteur Institute) was induced by delivering
100 bacteria split into the nasal cavities (20 L each) of mice
under xylazine-ketamine anesthesia, as described elsewhere
[38], in sterile isolators in a biohazard animal unit. M. tubercu-
losis–infected mice were killed 3 or 9 weeks after infection.
Determination of colony-forming units from infected organs.
The number of viable bacteria recovered from frozen organs was
evaluated as described elsewhere [22, 38].
Lipopolysaccharide (LPS) challenge. Two weeks after M.
bovis BCG infection, mice were challenged intraperitoneally
with 0.1 g of LPS from E. coli (serotype 0111:B4; Sigma) per
gram of body weight and killed 8 h later.
Evaluation of serum and spleen cytokine levels and serum
enzymes. Blood samples from retroorbital sinuses were ob-
tained 2 and 4 weeks after M. bovis BCG infection and 8 h after
LPS challenge. The amounts of solTNF, interferon (IFN)–,
interleukin (IL)– 6, and soluble TNFR1 were determined by
ELISA. Spleens were homogenized in 0.04% Tween 80/saline
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buffer (125 mg of tissue per mL), as described elsewhere [39].
IL-12p70 and IL-4 were evaluated by ELISA using serial dilu-
tions (sensitivity, 5–2000 pg/mL; Diaclone or R&D Systems).
The murine TNF ELISA used does not cross-react with
XENP1595, an engineered version of human solTNF. Hepa-
tocyte damage was assessed by measuring serum enzyme ac-
tivities of aspartate aminotransferase (AST) and alanine ami-
notransferase (ALT), as reported elsewhere [39].
TNF bioactivity assays on WEHI 164 cells. The bioactiv-
ity of TNF in mouse serum samples was measured on WEHI
164 cells (subclone 13) compared with standard murine TNF.
WEHI 164 cells (3  104 cells/well) were incubated in the pres-
ence of actinomycin D (1 g/mL) with mouse serum (3-fold
serial dilutions from 1:10 to 1:21,000 for serum samples fromM.
bovis BCG–infected mice and from 1:20 to 1:1  106 for serum
samples from BCG/LPS-treated mice) for 20 h in a 96-well plate.
Cell viability was assessed as described elsewhere [40]. Addition
of solTNFR1 (5g/mL) or anti-TNF (2g/mL) totally inhibited
the TNF bioactivity of serum samples.
Histological analyses. Liver and lung samples were fixed in
4% buffered formaldehyde and embedded in paraffin for subse-
quent hematoxylin-eosin staining.
Statistical analyses. The unpaired Student’s t test was used
for analyses. Differences were considered statistically significant
at P  .05.
RESULTS
No suppression of host immunity due to blocking of solTNF
with DN-TNF during M. bovis BCG and M. tuberculosis
infections. To determine whether selective blocking of solTNF
may alter host protection against M. bovis BCG, mice were in-
fected with 1  107 living M. bovis BCG and treated twice
weekly (30 mg/kg) with XENP1595, a selective inhibitor of
solTNF, or etanercept, which blocks both solTNF and tmTNF
[4, 28, 29]. At 4 weeks after M. bovis BCG infection, etanercept-
treated mice showed increased bacterial loads in lungs, spleen,
and liver, but infected organs of XENP1595-treated mice had
Figure 1. Better control of Mycobacterium bovis bacillus Calmette-Guérin (BCG) and Mycobacterium tuberculosis infections exhibited by vehicle-
treated and dominant-negative tumor necrosis factor (DN-TNF)–treated mice than etanercept-treated mice. Mice were injected with vehicle, etanercept
(etan), or XENP1595 1 day before M. bovis BCG infection and twice weekly thereafter at 30 mg/kg. A, Bacterial loads in lungs (n  9–11 per group),
spleen (n  12–14 per group), and liver (n  12–14 per group) 4 weeks after intravenous inoculation with 1  107 cfu of M. bovis BCG. Data are
means  SEs. B, Bacterial loads in lungs and liver on day 22 after intranasal infection with 100 cfu of M. tuberculosis. Data are means  SEs (n  4
per group). C, Percent change in body weight after M. tuberculosis infection, as described for panel B. Data are means  SEs (n  7– 8 per group).
*P  .04 and **P  .003, for the comparison with vehicle-treated mice. MTB, M. tuberculosis.
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bacterial loads similar to those in control mice (figure 1A). Simi-
larly,M. tuberculosis–infected mice treated with etanercept showed
higher bacterial loads on day 22 (mainly in lungs), whereas control
of bacillary growth in XENP1595-treated mice was similar to that in
vehicle-treated mice (figure 1B). At this time point, etanercept-
treated mice rapidly lost body weight, as did TNF/mice, whereas
weight loss in XENP1595-treated mice was similar to that in
vehicle-treated mice (figure 1C). In addition, all 4 etanercept-
treated mice died of infection between days 22 and 28, whereas only
1 of 4 XENP1595-treated mice died, on day 29; the other 3 survived
the 9 weeks of the experiment. These results suggest that selective
blockade of solTNF by a DN-TNF biologic during infection has
minimal effect on host protection, whereas inhibition of both
solTNF and tmTNF by etanercept suppresses immunity toM.bovis
BCG and M. tuberculosis infections.
Effect of blocking solTNF on M. bovis BCG–induced Th1
and Th2 cytokines. To determine whether treatment with
TNF inhibitors affects M. bovis BCG–induced Th1/Th2 cyto-
kines, the levels of IFN-, IL-12p70, and IL-4 were evaluated in
the serum and in the spleen. Figure 2A shows that serum IFN-
levels in XENP1595-treated mice were lower than those induced
in control mice 2 weeks after infection; in contrast, IFN- was
not activated in etanercept-treated mice. Because levels of IL-
12p70 were undetectable in serum, IL-12p70 was quantified in
the spleen. At 4 weeks after infection, IL-12p70 levels were sim-
ilar in vehicle- and XENP1595-treated mice but were signifi-
cantly decreased in etanercept-treated mice (figure 2B). To de-
termine the effect of TNF inhibitors on the Th2 immune
response, IL-4 was quantified in the spleen 4 weeks after infec-
tion; IL-4 levels in etanercept-and XENP1595-treated mice were
similar to those in control mice (figure 2C). These results suggest
that selective inhibition of solTNF by XENP1595 weakens Th1
immune responses somewhat but much less than the pro-
nounced inhibition observed when both solTNF and tmTNF are
neutralized by etanercept.
Effect of anti-TNF biologics onM. bovis BCG–induced TNF
levels. M. bovis BCG induces TNF release, which can be eval-
uated in serum after intravenous infection [18]. Immunoreac-
tive TNF was therefore quantified at different time points after
infection and treatment with TNF inhibitors. Etanercept treat-
ment decreased immunoreactive TNF levels at 2 weeks after in-
fection, whereas XENP1595 treatment dramatically increased it
compared with findings in vehicle-treated control mice (figure
3A). This increase was probably due to subunit exchange of
the DN-TNF trimer with mouse TNF trimer, which results in
a stabilized heterotrimer lacking TNF biological activity [27,
28]. To determine whether M. bovis BCG–induced TNF could
stimulate TNF receptor signaling, bioactivity was assessed us-
ing WEHI 164 cells, which are highly sensitive to TNF [40].
Serum from BCG-infected mice treated with LPS was toxic to
cells because of high levels of solTNF; in contrast, serum from
XENP1595-, etanercept-, and vehicle-treated mice did not
exhibit bioactivity after infection (figure 3B), suggesting that
solTNF formed complexes with etanercept or mouse solTNF
receptor or formed heterotrimers with XENP1595, thereby
preventing solTNF signaling. Soluble TNFR1 serum levels
progressively increased throughout the infection, with all
groups showing similar levels (figure 3C); this increase in
TNFR1 levels may have contributed to the inhibition of TNF
bioactivity seen in BCG-infected mice.
Figure 2. Effect of tumor necrosis factor (TNF) inhibitors on Mycobac-
terium bovis bacillus Calmette-Guérin (BCG)–induced activation of inter-
feron (IFN)–, interleukin (IL)–12p70, and IL-4. A, Serum IFN- evaluated
in M. bovis BCG–infected mice (n  7–12 per group). B, Splenic IL-
12p70 evaluated 4 weeks after M. bovis BCG infection (n  13–14 per
group). C, Splenic IL-4 evaluated 4 weeks after M. bovis BCG infection
(n  13–14 per group). Data are means  SEs and are representative
of 2 independent experiments. *P  .02 and **P  .001, for the com-
parison with vehicle-treated mice.
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Effect of anti-TNF biologics on granuloma formation after
M. bovis BCG or M. tuberculosis infection. Hepatic granu-
lomas of M. bovis BCG–infected XENP1595-treated mice did
not differ in morphology or number compared with those of
control mice 2 weeks after infection, whereas those of
etanercept-treated mice were smaller and fewer, contained fewer
cells (figure 4A– 4D), and resembled those found in mice ex-
pressing high amounts of solTNFR1-IgG, as previously reported
[18]. After M. tuberculosis infection, acute pulmonary infection,
as illustrated by an increase in lung weight, was found in
etanercept-treated mice and in TNF/mice 3 weeks after infec-
tion, whereas lung weight in XENP1595-treated mice was simi-
lar to that in control mice at 3 and 9 weeks after infection (data
not shown). Macroscopically, the lungs of etanercept-treated
mice displayed large confluent nodules similar to those seen in
TNF/ mice, whereas XENP1595-treated mice had smaller,
better-defined nodules similar to those in control mice (figure
5A–5D). Microscopically, the lungs of etanercept-treated mice
presented large necrotic lesions and significant inflammation,
comparable to findings in TNF/mice. In contrast, XENP1595-
treated mice showed slightly more prominent lung pathology
than did control mice, with few foci of necrosis and overall in-
Figure 3. Effect of tumor necrosis factor (TNF) inhibitors on Mycobacterium bovis bacillus Calmette-Guérin (BCG)–induced immunoreactive and
bioactive TNF and soluble TNF receptor 1 (sTNFR1) levels. A, Immunoreactive TNF quantified by ELISA 2 and 4 weeks after M. bovis BCG infection
(n  12–14 per group). B, Bioactive TNF evaluated by cytotoxicity against WEHI 164 cells, using serum obtained from M. bovis BCG–infected mice
2 weeks after infection. Serial serum dilutions were tested on sensitive cells. In mice challenged with BCG alone, no serum (from vehicle-, etanercept-,
or XENP1595-treated mice) showed toxicity relative to recombinant TNF (rTNF) controls. In contrast, serum from BCG/lipopolysaccharide (LPS)–
challenged mice demonstrated high toxicity because of soluble TNF, as confirmed by its neutralization after addition of sTNFR1-IgG. C, sTNFR1 quantified
during M. bovis BCG infection (n  7–10 per group). Data are means  SEs and are representative of 2 independent experiments. *P  .01 and
**P  .001, for the comparison with vehicle-treated mice. OD, optical density.
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flammatory changes comparable to those in control mice (figure
5E–5H). Lung scores for inflammation, neutrophil infiltration,
and necrosis as well as the extent of free air space showed that
etanercept-treated mice were as sensitive as TNF/ mice,
whereas XENP1595-treated mice were indistinguishable from
control mice, with the exception of a modest but significant in-
crease in lung necrosis (figure 5I and 5J).
Protection conferred by anti-TNF biologics from acute liver
injury induced by LPS challenge in M. bovis BCG–infected
mice. After M. bovis BCG infection, formation of liver gran-
ulomas and recruitment of immune cells can mediate hepatic
injury secondary to granulomatous containment of bacteria,
as monitored by serum levels of AST and ALT, 2 enzymes that
correlate with liver damage [39]. Etanercept-treated mice
showed significantly lower levels of serum AST and ALT than
did vehicle- or XENP1595-treated mice at 2 weeks after infec-
tion, which may have been due to the significant reduction in
the number of hepatic granulomas compared with that in
XENP1595-treated and control mice (figure 6A). Administra-
tion of endotoxin to M. bovis BCG–infected mice causes a
massive release of hepatotoxic factors that is mediated by
TNF and inducible nitric oxide synthase [39]. To determine
whether blockade of solTNF with either etanercept or
XENP1595 during M. bovis BCG infection protects from this
endotoxin-induced hepatic injury, liver enzymes were quan-
tified 8 h after LPS challenge. As expected, etanercept-treated
mice were protected from secondary liver injury, owing to the
reduced number of liver granulomas. Blocking of solTNF
with XENP1595 showed a moderate but significant liver pro-
tection, with transaminase levels decreased compared with
those in control mice (figure 6B). In addition, bioactive
solTNF, IL-6, and IFN- serum levels were significantly re-
duced in M. bovis BCG–infected mice treated with etanercept or
XENP1595 (figure 6C). These data confirm that both a TNFR2–
IgG1 Fc fusion protein and a DN-TNF biologic protect from
liver injury induced by endotoxin in M. bovis BCG–infected
mice, and they suggest that tmTNF plays an important role in
the local inflammatory response to M. bovis BCG infection,
whereas solTNF plays a larger role in the acute inflammation
mediated by LPS.
Figure 4. Granuloma formation after Mycobacterium bovis bacillus Calmette-Guérin (BCG) infection. A–C, Liver sections obtained 2 weeks after M.
bovis BCG infection, showing well-differentiated granulomas in vehicle-treated (A) and XENP1595-treated (B) mice compared with small and poorly
differentiated granulomas in etanercept-treated mice (C) (hematoxylin-eosin staining; original magnification, 400). These results are representative of
2 independent experiments (n  5 per group). D, Quantification of liver granulomas 2 weeks after infection. The results showed a reduced no. in
etanercept-treated mice, whereas the no. in XENP1595-treated mice was comparable to that in control mice (n  5 per group). Data are means  SEs.
**P  .001, for the comparison with vehicle-treated mice.
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DISCUSSION
The extension of anti-TNF biologics for use in the treatment of
inflammatory diseases beyond rheumatoid arthritis and Crohn
disease increases the patient population exposed to the risk of
infections and other complications associated with these thera-
pies. Thus, to maximize the number of patients who are able to
benefit from anti-TNF therapies, new therapeutic strategies are
required to attenuate the deleterious effects that total TNF
blockade has on the host immune system while maintaining the
positive anti-inflammatory effects. In support of this goal, recent
data obtained in mouse genetic models and in experimental
models of inflammatory and infectious diseases suggest that se-
lective inhibitors of solTNF that spare tmTNF may be anti-
inflammatory while maintaining innate immunity to infection
[22–25, 41]. Existing anti-TNF drugs have multiple targets: they
can inhibit both tmTNF- and solTNF-mediated forward signal-
ing by sequestration, stimulate tmTNF-mediated reverse signal-
Figure 5. Pulmonary lesions and pathological analyses of mice infected with Mycobacterium tuberculosis. Macroscopic (A–D) and microscopic (E–H)
examinations of pulmonary lesions were performed 22 days after intranasal infection with 100 cfu of M. tuberculosis in mice receiving saline (A and
E), etanercept (B and F), or XENP1595 (C and G) as well as in tumor necrosis factor (TNF)/ mice (D and H) (original magnification, 400). Necrotic
lesions (arrows) are present in etanercept-treated mice and are more predominant in TNF/ mice, which may develop caseous necrosis. I, Lung
pathology, including inflammation, polymorphonuclear leukocyte (PMN) infiltration, and necrosis, scored 22 days after infection (0, no alteration; 1–5,
increasing severity of pathological lesions). etan, etanercept. J, Free air space expressed as the area of 5 lung cross-sections (percentage). Data are
means  SEs (n  4 per group). *P  .05, for the comparison with vehicle-treated mice.
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ing by cross-linking, and trigger immune cell effector functions
against tmTNF-expressing cells via their IgG1 Fc domains [4].
Etanercept can also inhibit LT and LT, which increases sus-
ceptibility to mycobacterial infections in animal models [4, 16,
42, 43]. In contrast, DN inhibitors of TNF are a new class of
selective solTNF blockers that are based on variants of native
human solTNF [27, 28, 34]. These agents eliminate solTNF ho-
motrimers but do not bind to or interact with tmTNF or LT
(figure 7); consequently, they cannot block forward or reverse
signaling by these cytokines. Moreover, in contrast to the 3 clin-
ically available biologics, DN-TNFs possess no antibody Fc do-
main and are thus incapable of stimulating Fc-mediated im-
mune cell effector functions.
The present study explores the in vivo consequences of selec-
tively blocking solTNF with XENP1595, a pegylated DN-TNF
biologic, versus blocking both solTNF and tmTNF with etaner-
cept, a TNFR2-IgG1 Fc fusion protein. The effects of these anti-
TNF agents were compared during M. bovis BCG and M. tuber-
culosis infections and in acute liver injury induced by endotoxin
in M. bovis BCG–infected mice. Selective inhibition of solTNF
by XENP1595 did not affect bacterial load after M. bovis BCG or
M. tuberculosis infection, whereas etanercept increased the num-
ber of viable mycobacteria in infected organs. Infection by a vir-
ulent strain of M. tuberculosis resulted in a 1 log increase in
bacterial load in etanercept-treated and TNF/mice, compared
with that in the other groups. Recently, it has been shown that
treatment with a murine homologue of etanercept and with an
anti-TNF antibody resulted in 100% mortality during acute M.
tuberculosis infection and that both inhibitory agents also sensi-
tized mice to chronicM. tuberculosis infection, with the antibody
being more immunosuppressive [19]. This finding was ascribed
not to differences in TNF inhibitory mechanisms but to reduced
penetration or retention of murine etanercept in granulomas
relative to the anti-TNF antibody. In agreement with this report,
Figure 6. Levels of liver enzymes and cytokines after Mycobacterium bovis bacillus Calmette-Guérin (BCG) infection plus lipopolysaccharide (LPS)
challenge. Mice were treated with vehicle, etanercept (etan), or XENP1595 1 day before M. bovis BCG infection and then twice a week at 30 mg/kg;
2 weeks after BCG infection, mice were injected with LPS. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) serum levels were
measured 2 weeks after M. bovis BCG infection (A) and 8 h after LPS (0.1 g/g) challenge (BCG/LPS) (B). Serum levels of bioactive tumor necrosis factor
(TNF), interleukin (IL)– 6, and interferon (IFN)– (C) were reduced in mice treated with TNF inhibitors, showing protection in BCG/LPS-treated mice. Data
are means  SEs and are representative of 2 independent experiments (n  7–10 per group). *P  .03 and **P  .001, for the comparison with
vehicle-treated mice.
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our data show a pronounced effect of etanercept on bacillary
growth in lungs during acute M. tuberculosis infection, which
was not detected in XENP1595-treated mice. Etanercept-treated
mice infected by M. tuberculosis developed dramatic lung in-
flammation with necrotic pneumonia and disseminated infec-
tion comparable to that observed in TNF/ mice. This finding
suggests that inhibiting both solTNF and tmTNF has potent ef-
fects, whereas inhibiting solTNF has very limited effects during
acute M. tuberculosis infection.
Although etanercept treatment increased the number of via-
ble M. bovis BCG by only 2-fold, an inhibitory effect on IFN-
and IL-12p70 was observed, suggesting a modification of Th1
immune responses. Systemic IFN- was also decreased in DN-
TNF–treated mice 2 weeks after infection, but the extent of this
effect was equivalent to that found in mice expressing only
tmTNF (TNF/LT/), which are able to survive similar exper-
imental M. bovis BCG infection, as previously reported [22].
These data suggest that, compared with etanercept, XENP1595
better preserves the Th1 immune response induced by acute M.
bovis BCG infection. In addition, our data show that M. bovis
BCG liver granuloma formation was not altered by treatment
with XENP1595. In contrast, etanercept-treated mice presented
with poor granuloma formation and deficient cell recruitment,
correlating with the higher number of living mycobacteria in
infected organs than in other experimental groups and suggest-
ing that tmTNF activity is important in the development of bac-
tericidal granulomas.
Possibly because of a reduction in the number of inflamma-
tory and immune cells in the liver, M. bovis BCG–infected mice
treated with etanercept showed decreased hepatic injury com-
pared with control and DN-TNF-treated mice, as assessed by
serum transaminase levels. These data suggest that XENP1595,
by preserving tmTNF activity, allows granuloma cell recruit-
ment and thereby maintains anti-mycobacterial host defense.
However, it was critical to clarify whether this solTNF-selective
biologic remained able to protect M. bovis BCG–infected mice
Figure 7. Mechanisms of action of a decoy receptor for soluble tumor necrosis factor (TNF) receptor 2 (TNFR2) and of dominant-negative TNF
(DN-TNF). Transmembrane TNF (tmTNF) on effector cells (green) binds to TNF receptors on target cells (red) and signals through cell-cell contact
(juxtacrine signaling). Soluble TNF (solTNF) is produced by TACE (TNF-– converting enzyme) cleavage of tmTNF and subsequently binds to TNF receptors
to stimulate paracrine and/or autocrine signaling. Etanercept (TNFR2-Fc decoy receptor) (blue) binds to and sequesters both tmTNF and solTNF, blocking
both routes of TNF signaling, and also binds to and inhibits LT. In contrast, XENP1595, a mutated form of human solTNF with disrupted receptor-binding
interfaces (DN-TNF) (orange), eliminates solTNF by means of a subunit exchange mechanism but is unable to interact with tmTNF. Thus, XENP1595
inhibits solTNF signaling without suppressing tmTNF- or LT-mediated responses.
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from acute liver injury caused by endotoxin-induced TNF.
XENP1595-treated mice, like etanercept-treated mice, were sig-
nificantly protected fromM. bovisBCG/LPS–induced liver dam-
age, as assessed by a reduction in serum transaminase levels as
well as in bioactive TNF, IL-6, and IFN- levels. This result for
the DN-TNF biologic is in agreement with our previous findings
showing thatM. bovis BCG/LPS–induced liver damage is depen-
dent on solTNF, because mice lacking solTNF but expressing
tmTNF also showed protection [22].
TNF is involved in the pathogenesis of human inflamma-
tory and autoimmune diseases but is also essential in host
defense mechanisms. Its nonselective neutralization is known
to compromise host immunity and is associated with new
tuberculosis infections and reactivation of latent infections in
humans and mice [2, 5–10]. Notably, computational model-
ing of tuberculosis infection rates for etanercept and inflix-
imab suggests that these agents sensitize humans to both
newly acquired and latent tuberculosis [44, 45]. New infec-
tion represented almost half of all tuberculosis cases in pa-
tients treated with etanercept, whereas reactivation was pre-
dominant for infliximab [45]. Our study investigated only
acute tuberculosis infection in mice, but another recent
mouse study using a virus-based vaccine selectively targeting
solTNF [46] lends support to our hypothesis; its findings
showed that by inhibiting only solTNF one can achieve pro-
tection from arthritis without inducing either newly acquired
or reactivated tuberculosis. Given that nonselective anti-TNF
therapies, such as decoy receptors and monoclonal antibod-
ies, have proved efficacious for severe inflammatory disease,
the development of selective inhibitors of solTNF may repre-
sent a logical next-generation strategy. Data showing that
DN-TNF biologics attenuate arthritis without suppressing
immunity to L. monocytogenes in mouse models further sup-
port our hypothesis [28]. These 2 independent reports from
studies using a vaccine and a biologic, along with extensive
data from mouse genetic models, suggest that selective inhi-
bition of solTNF does not suppress immune responses to
granulomatous infections. It will be valuable to repeat these
studies using mouse models of tuberculosis reactivation, to
compare all 3 classes of anti-TNF biologics and ultimately to
determine whether these findings will have clinical relevance.
In conclusion, the present study shows that a DN-TNF bio-
logic that selectively inhibits solTNF did not suppress host im-
munity to M. bovis BCG and M. tuberculosis infections but did
protect mice from M. bovis BCG/LPS–induced liver injury. This
suggests that the risks associated with the first generation of non-
selective TNF inhibitors might be reduced by use of a DN-TNF
biologic that spares the protective effects of tmTNF. A reduction
in the infection risks associated with current anti-TNF drugs
may also allow the safer use of novel anti-TNF therapies in other
inflammatory diseases.
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